porfimer sodium porfimer sodium porfimer sodium, sold as photofrin, is a photosensitizer used in photodynamic therapy and radiation therapy and for palliative treatment of obstructing endobronchial non-small cell lung carcinoma and obstructing esophageal cancer. porfimer sodiumclinical dataahfs/drugs.comconsumer drug informationlicense data eu ema: by inn us fda: photofrin routes ofadministrationintravenousatc codel01xd01 (who) legal statuslegal status us: ℞-only pharmacokinetic databioavailabilitynaprotein binding~90%elimination half-life21.5 days (mean)excretionfecalidentifierscas number87806-31-3 yethyl ether: 97067-70-4 ypubchem cid57166drugbankdb00707 nchemspider10482283 yuniiy3834sik5fethyl ether: 625j2hs54g ychemblchembl1201707 nchemical and physical dataformulac68h74n8o11 (for n=0)molar mass1179.36 g/mol (for n=0) g·mol−13d model (jsmol)interactive image smiles .cc(o)c1=c(c)c=2c=c5nc(=cc4=nc(=cc=3nc(c=c1n=2)=c(c)c=3ccc(o)=o)c(ccc(o)=o)=c4c)c(c)=c5c(c)oc(c)c6=c(c)c=7c=c%10nc(=cc9=nc(=cc=8nc(c=c6n=7)=c(c)c=8ccc(o)=o)c(ccc(o)=o)=c9c)c(c)=c%10c(c)o inchi inchi=1s/c68h74n8o11.na/c1-29-41(13-17-61(79)80)53-28-56-44(16-20-64(85)86)32(4)48(72-56)24-59-68(36(8)52(76-59)25-58-65(37(9)77)33(5)49(73-58)21-45(29)69-53)40(12)87-39(11)67-35(7)50-22-46-30(2)42(14-18-62(81)82)54(70-46)27-55-43(15-19-63(83)84)31(3)47(71-55)23-57-66(38(10)78)34(6)51(74-57)26-60(67)75-50;/h21-28,37-40,71-73,75,77-78h,13-20h2,1-12h3,(h,79,80)(h,81,82)(h,83,84)(h,85,86);/q;+1/b45-21-,46-22-,47-23-,48-24-,49-21-,50-22-,51-26-,52-25-,53-28-,54-27-,55-27-,56-28-,57-23-,58-25-,59-24-,60-26-; ykey:cgqhmicgjykffj-zljvsrbasa-n y ny (what is this?) (verify) porfimer is a mixture of oligomers formed by ether and ester linkages of up to eight porphyrin units. in practice, a red light source emitting at 630 nm is used to excite the porfimer oligomers. porfimer is haematoporphyrin derivative (hpd) (see pdt). approvals and indications it was approved in canada in 1993 for the treatment of bladder cancer. it was approved in japan in 1994 (for early stage lung cancer?). it was approved by the u.s. fda in december 1995 for esophageal cancer, and in 1998, it was approved for the treatment of early non-small cell lung cancer. in august 2003 the fda approved its use for barrett's esophagus.